{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T14:05:35Z","timestamp":1794492335693,"version":"4.9.1"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T00:00:00Z","timestamp":1761091200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T00:00:00Z","timestamp":1761091200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hum Genomics"],"DOI":"10.1186\/s40246-025-00836-4","type":"journal-article","created":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T08:26:39Z","timestamp":1761121599000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["The role of ABCB1 and CES1 genotypes on the efficacy and safety of dabigatran: a systematic review and meta-analysis"],"prefix":"10.1186","volume":"19","author":[{"given":"Weam","family":"Aldiban","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nada G.","family":"Hamam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nereen A.","family":"Almosilhy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kholoud","family":"Elsamman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Wagdy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doaa","family":"Mashaly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suhel F.","family":"Batarseh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youssef","family":"El-Sherif","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Basma Badrawy","family":"Khalefa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zina","family":"Otmani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,22]]},"reference":[{"issue":"9","key":"836_CR1","doi-asserted-by":"publisher","first-page":"603","DOI":"10.2217\/cer-2020-0013","volume":"9","author":"V Allan","year":"2020","unstructured":"Allan V, Ramagopalan SV, Mardekian J, Jenkins A, Li X, Pan X, et al. Propensity score matching and inverse probability of treatment weighting to address confounding by indication in comparative effectiveness research of oral anticoagulants. J Comp Eff Res. 2020;9(9):603\u201314.","journal-title":"J Comp Eff Res"},{"issue":"9","key":"836_CR2","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1007\/s00228-013-1510-z","volume":"69","author":"S Harder","year":"2013","unstructured":"Harder S, Graff J. Novel oral anticoagulants: clinical pharmacology, indications and practical considerations. Eur J Clin Pharmacol. 2013;69(9):1617\u201333.","journal-title":"Eur J Clin Pharmacol"},{"key":"836_CR3","doi-asserted-by":"crossref","unstructured":"Nguyen A, Dasgupta A, Wahed A. Management of hemostasis and coagulopathies for surgical and critically ill patients: an evidence-based approach. Management of hemostasis and coagulopathies for surgical and critically ill patients: an evidence-based approach. Elsevier. 2016; p: 39\u201372. 1\u2013164 p.","DOI":"10.1016\/B978-0-12-803531-3.00003-3"},{"issue":"3","key":"836_CR4","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1007\/s11239-016-1446-0","volume":"43","author":"A Zirlik","year":"2017","unstructured":"Zirlik A, Bode C. Vitamin K antagonists: relative strengths and weaknesses vs. direct oral anticoagulants for stroke prevention in patients with atrial fibrillation. J Thromb Thrombolysis. 2017;43(3):365\u201379.","journal-title":"J Thromb Thrombolysis"},{"issue":"12","key":"836_CR5","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.1104","volume":"12","author":"Q Xiang","year":"2022","unstructured":"Xiang Q, Xie Q, Liu Z, Mu G, Zhang H, et al. Genetic variations in relation to bleeding and pharmacodynamics of Dabigatran in Chinese patients with nonvalvular atrial fibrillation: a nationwide multicentre prospective cohort study. Clin Transl Med. 2022;12(12):e1104. https:\/\/doi.org\/10.1002\/ctm2.1104.","journal-title":"Clin Transl Med"},{"key":"836_CR6","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.bcp.2016.09.003","volume":"119","author":"J Shi","year":"2016","unstructured":"Shi J, Wang X, Nguyen JH, Bleske BE, Liang Y, Liu L, et al. Dabigatran etexilate activation is affected by the CES1 genetic polymorphism G143E (rs71647871) and gender. Biochem Pharmacol. 2016;119:76\u201384.","journal-title":"Biochem Pharmacol"},{"issue":"1","key":"836_CR7","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1001\/jamainternmed.2014.5398","volume":"175","author":"I Hernandez","year":"2015","unstructured":"Hernandez I, Baik SH, Pi\u00f1era A, Zhang Y. Risk of bleeding with Dabigatran in atrial fibrillation. JAMA Intern Med. 2015;175(1):18\u201324.","journal-title":"JAMA Intern Med"},{"key":"836_CR8","doi-asserted-by":"publisher","DOI":"10.3390\/jpm10030133","volume":"10","author":"AN Ro\u015fian","year":"2020","unstructured":"Ro\u015fian AN, Iancu M, Trifa AP, Ro\u015fian \u015eH, Mada C, Gocan CP, et al. An exploratory association analysis of ABCB1 rs1045642 and ABCB1 rs4148738 with non-major bleeding risk in atrial fibrillation patients treated with Dabigatran or Apixaban. J Pers Med. 2020;10:133.","journal-title":"J Pers Med"},{"issue":"3","key":"836_CR9","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1002\/cpt.2316","volume":"110","author":"J L\u00e4hteenm\u00e4ki","year":"2021","unstructured":"L\u00e4hteenm\u00e4ki J, Vuorinen AL, Pajula J, Harno K, Lehto M, Niemi M, van Gils M. Pharmacogenetics of bleeding and thromboembolic events in direct oral anticoagulant users. Clin Pharmacol Ther. 2021;110(3):768\u201376. https:\/\/doi.org\/10.1002\/cpt.2316. Epub 2021 Jun 26.","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"836_CR10","doi-asserted-by":"publisher","first-page":"2247","DOI":"10.1186\/s12872-022-02910-4","volume":"22","author":"Z Zhu","year":"2022","unstructured":"Zhu Z, Qian C, Su C, Tao H, Mao J, Guo Z, et al. The impact of ABCB1 and CES1 polymorphisms on the safety of Dabigatran in patients with non-valvular atrial fibrillation. BMC Cardiovasc Disord. 2022;22(1):2247\u201355.","journal-title":"BMC Cardiovasc Disord"},{"issue":"2","key":"836_CR11","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1111\/jth.13577","volume":"15","author":"I Gouin-Thibault","year":"2017","unstructured":"Gouin-Thibault I, Delavenne X, Blanchard A, Siguret V, Salem JE, Narjoz C, et al. Interindividual variability in Dabigatran and Rivaroxaban exposure: contribution of ABCB1 genetic polymorphisms and interaction with clarithromycin. J Thromb Haemost. 2017;15(2):273\u201383.","journal-title":"J Thromb Haemost"},{"issue":"3","key":"836_CR12","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1197\/jamia.M2270","volume":"14","author":"G Par\u00e9","year":"2007","unstructured":"Par\u00e9 G, Jaana M, Sicotte C. Systematic review of home telemonitoring for chronic diseases: the evidence base. J Am Med Inform Assoc. 2007;14(3):269\u201377.","journal-title":"J Am Med Inform Assoc"},{"key":"836_CR13","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.","journal-title":"BMJ"},{"key":"836_CR14","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898.","journal-title":"BMJ"},{"issue":"13","key":"836_CR15","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1002\/sim.1461","volume":"22","author":"N Terrin","year":"2003","unstructured":"Terrin N, Schmid CH, Lau J, Olkin I. Adjusting for publication bias in the presence of heterogeneity. Stat Med. 2003;22(13):2113\u201326.","journal-title":"Stat Med"},{"issue":"7109","key":"836_CR16","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","volume":"315","author":"M Egger","year":"1997","unstructured":"Egger M, Smith GD, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. Br Med J. 1997;315(7109):629\u201334.","journal-title":"Br Med J"},{"key":"836_CR17","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/1471-2288-14-45","volume":"14","author":"C-LMD Lo","year":"2014","unstructured":"Lo C-LMD, Newcastle-Ottawa LM. Scale: comparing reviewers\u2019 to authors\u2019 assessments. BMC Med Res Methodol. 2014;14:45.","journal-title":"BMC Med Res Methodol"},{"key":"836_CR18","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2022.873031","volume":"13","author":"Q Xie","year":"2022","unstructured":"Xie Q, Li Y, Liu Z, Mu G, Zhang H, Zhou S, et al. SLC4A4, FRAS1, and SULT1A1 genetic variations associated with Dabigatran metabolism in a healthy Chinese population. Front Genet. 2022;13:873031. https:\/\/doi.org\/10.3389\/fgene.2022.873031.","journal-title":"Front Genet"},{"issue":"8","key":"836_CR19","first-page":"477","volume":"14","author":"Y Liu","year":"2021","unstructured":"Liu Y, Yang C, Qi W, Pei Z, Xue W, Zhu H, et al. The impact of abcb1 and ces1 polymorphisms on Dabigatran pharmacokinetics in healthy Chinese subjects. Pharmgenomics Pers Med. 2021;14(8):477\u201385.","journal-title":"Pharmgenomics Pers Med"},{"issue":"4","key":"836_CR20","doi-asserted-by":"publisher","first-page":"e362","DOI":"10.1097\/MJT.0000000000001710","volume":"31","author":"A Olserov\u00e1","year":"2024","unstructured":"Olserov\u00e1 A, Jansk P, Magerov\u00e1 H, Sr\u00e1mkov\u00e1 T, Kesnerov\u00e1 P, Kmetonyov\u00e1 S, et al. The effect of ABCB1 and CES1 polymorphisms on plasma levels of Dabigatran and risk of hemorrhagic complications in ischemic stroke patients. Am J Ther. 2024;31(4):e362\u201371.","journal-title":"Am J Ther"},{"issue":"5","key":"836_CR21","first-page":"333","volume":"45","author":"T Veleta","year":"2024","unstructured":"Veleta T, Beranek M, Tacheci I, Dulicek P, Maly R, Cermakova E, et al. Pharmacogenetics of dabigatran and apixaban in association with gastrointestinal bleeding. Neuro Endocrinol Lett. 2024;45(5):333\u201340.","journal-title":"Neuro Endocrinol Lett"},{"issue":"8","key":"836_CR22","doi-asserted-by":"publisher","first-page":"3537","DOI":"10.1007\/s12325-020-01414-x","volume":"37","author":"P Zubiaur","year":"2020","unstructured":"Zubiaur P, Saiz-Rodr\u00edguez M, Ochoa D, Navares-G\u00f3mez M, Mej\u00eda G, Rom\u00e1n M, et al. Effect of sex, use of pantoprazole and polymorphisms in SLC22A1, ABCB1, CES1, CYP3A5 and CYP2D6 on the pharmacokinetics and safety of dabigatran. Adv Ther. 2020;37(8):3537\u201350.","journal-title":"Adv Ther"},{"key":"836_CR23","first-page":"127","volume":"11","author":"DA Sychev","year":"2018","unstructured":"Sychev DA, Levanov AN, Shelekhova TV, Bochkov PO, Denisenko NP, Ryzhikova KA, et al. The impact of ABCB1 (rs1045642 and rs4148738) and CES1 (rs2244613) gene polymorphisms on Dabigatran equilibrium peak concentration in patients after total knee arthroplasty. Pharmgenomics Pers Med. 2018;11:127\u201337.","journal-title":"Pharmgenomics Pers Med"},{"key":"836_CR24","doi-asserted-by":"publisher","DOI":"10.1515\/dmpt-2019-0029","author":"D Sychev","year":"2020","unstructured":"Sychev D, Skripka A, Ryzhikova K, Bochkov P, Shevchenko R, Krupenin P, et al. Effect of CES1 and ABCB1 genotypes on the pharmacokinetics and clinical outcomes of Dabigatran etexilate in patients with atrial fibrillation and chronic kidney disease. Drug Metab Pers Ther. 2020. https:\/\/doi.org\/10.1515\/dmpt-2019-0029","journal-title":"Drug Metab Pers Ther"},{"issue":"9","key":"836_CR25","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13092545","volume":"13","author":"L Cumitini","year":"2024","unstructured":"Cumitini L, Renda G, Giordano M, Rolla R, Shail T, Sacchetti S, et al. Role of CES1 and ABCB1 genetic polymorphisms on functional response to Dabigatran in patients with atrial fibrillation. J Clin Med. 2024;13(9):2545.","journal-title":"J Clin Med"},{"issue":"5","key":"836_CR26","doi-asserted-by":"publisher","first-page":"2247","DOI":"10.1111\/bcp.14646","volume":"87","author":"Q Ji","year":"2021","unstructured":"Ji Q, Zhang C, Xu Q, Wang Z, Li X, Lv Q. The impact of ABCB1 and CES1 polymorphisms on Dabigatran pharmacokinetics and pharmacodynamics in patients with atrial fibrillation. Br J Clin Pharmacol. 2021;87(5):2247\u201355. https:\/\/doi.org\/10.1111\/bcp.14646.","journal-title":"Br J Clin Pharmacol"},{"key":"836_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.thromres.2016.05.025","volume":"144","author":"C Dimatteo","year":"2016","unstructured":"Dimatteo C, D\u2019Andrea G, Vecchione G, Paoletti O, Cappucci F, Tiscia GL, et al. Pharmacogenetics of Dabigatran etexilate interindividual variability. Thromb Res. 2016;144:1\u20135.","journal-title":"Thromb Res"},{"issue":"3","key":"836_CR28","first-page":"499","volume":"15","author":"A Abdrakhmanov","year":"2024","unstructured":"Abdrakhmanov A, Zholdybayeva E, Shaimerdinova A, Kulmambetova G, Abildinova S, Albayev R, et al. Genetic variants of ABCB1 and CES1 genes on dabigatran metabolism in the Kazakh population. Casp J Intern Med. 2024;15(3):499\u2013508.","journal-title":"Casp J Intern Med"},{"issue":"6","key":"836_CR29","doi-asserted-by":"publisher","DOI":"10.3390\/genes14061192","volume":"14","author":"A Abdrakhmanov","year":"2023","unstructured":"Abdrakhmanov A, Akilzhanova A, Shaimerdinova A, Zhalbinova M, Tuyakova G, Abildinova S, et al. The distribution of the genotypes of ABCB1 and CES1 polymorphisms in Kazakhstani patients with atrial fibrillation treated with DOAC. Genes. 2023;14(6):1192. https:\/\/doi.org\/10.3390\/genes14061192.","journal-title":"Genes"},{"issue":"30","key":"836_CR30","doi-asserted-by":"publisher","first-page":"3558","DOI":"10.2174\/1381612824666181018153641","volume":"24","author":"Q Xie","year":"2018","unstructured":"Xie Q, Xiang Q, Mu G, Ma L, Chen S, Zhou S, et al. Effect of ABCB1 genotypes on the pharmacokinetics and clinical outcomes of new oral anticoagulants: a systematic review and meta-analysis. Curr Pharm Des. 2018;24(30):3558\u201365. https:\/\/doi.org\/10.2174\/1381612824666181018153641.","journal-title":"Curr Pharm Des"},{"key":"836_CR31","doi-asserted-by":"publisher","first-page":"959916","DOI":"10.3389\/fcvm.2022.959916","volume":"9","author":"H Li","year":"2022","unstructured":"Li H, Zhang Z, Weng H, Qiu Y, Zubiaur P, Zhang Y, et al. Association between CES1 rs2244613 and the pharmacokinetics and safety of dabigatran: meta-analysis and quantitative trait loci analysis. Front Cardiovasc Med. 2022;9:959916.","journal-title":"Front Cardiovasc Med"},{"issue":"1","key":"836_CR32","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1038\/gim.2016.33","volume":"19","author":"M Kozyra","year":"2017","unstructured":"Kozyra M, Ingelman-Sundberg M, Lauschke VM. Rare genetic variants in cellular transporters, metabolic enzymes, and nuclear receptors can be important determinants of interindividual differences in drug response. Genet Med. 2017;19(1):20\u20139.","journal-title":"Genet Med"},{"issue":"1","key":"836_CR33","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s40246-018-0157-3","volume":"12","author":"M Ingelman-Sundberg","year":"2018","unstructured":"Ingelman-Sundberg M, Mkrtchian S, Zhou Y, Lauschke VM. Integrating rare genetic variants into pharmacogenetic drug response predictions. Hum Genomics. 2018;12(1):26. https:\/\/doi.org\/10.1186\/s40246-018-0157-3.","journal-title":"Hum Genomics"},{"key":"836_CR34","doi-asserted-by":"publisher","first-page":"1454612","DOI":"10.3389\/fphar.2024.1454612","volume":"15","author":"Z Yang","year":"2024","unstructured":"Yang Z, Tan WR, Li Q, Wang Y, Liu S, Chen L, et al. Population pharmacokinetic study of the effect of polymorphisms in the ABCB1 and CES1 genes on the pharmacokinetics of Dabigatran. Front Pharmacol. 2024;15:1454612.","journal-title":"Front Pharmacol"},{"issue":"7","key":"836_CR35","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1093\/aje\/kwj259","volume":"164","author":"JPA Ioannidis","year":"2006","unstructured":"Ioannidis JPA, Trikalinos TA, Khoury MJ. Implications of small effect sizes of individual genetic variants on the design and interpretation of genetic association studies of complex diseases. Am J Epidemiol. 2006;164(7):609\u201314.","journal-title":"Am J Epidemiol"},{"issue":"1","key":"836_CR36","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1093\/ije\/dyn147","volume":"38","author":"PR Burton","year":"2009","unstructured":"Burton PR, Hansell AL, Fortier I, Manolio TA, Khoury MJ, Little J, et al. Size matters: just how big is BIG? Quantifying realistic sample size requirements for human genome epidemiology. Int J Epidemiol. 2009;38(1):263\u201373.","journal-title":"Int J Epidemiol"},{"key":"836_CR37","unstructured":"https:\/\/www.pharmgkb.org\/chemical\/PA165110351\/variantAnnotation"}],"container-title":["Human Genomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40246-025-00836-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40246-025-00836-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40246-025-00836-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T08:26:41Z","timestamp":1761121601000},"score":1,"resource":{"primary":{"URL":"https:\/\/humgenomics.biomedcentral.com\/articles\/10.1186\/s40246-025-00836-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,22]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["836"],"URL":"https:\/\/doi.org\/10.1186\/s40246-025-00836-4","relation":{},"ISSN":["1479-7364"],"issn-type":[{"value":"1479-7364","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,22]]},"assertion":[{"value":"4 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}],"article-number":"121"}}